X4 Pharmaceuticals (XFOR) Payables (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Payables for 10 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 48.97% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (down 48.97% YoY), and the FY2025 full-year result was $5.7 million, down 33.93% from the prior year.
• Payables declined to $3.9 million in Q2 2026 per XFOR's latest filing, from $5.1 million in the prior quarter.
• Across five years, Payables topped out at $11.1 million in Q1 2025 and bottomed at $3.6 million in Q1 2022.
• Historically, Payables has averaged $6.7 million across 5 years, with a median of $6.9 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Payables jumped 114.0% in 2023, then tumbled 54.36% in 2026.
• Over 5 years, Payables stood at $7.8 million in 2022, then gained by 15.04% to $8.9 million in 2023, then retreated by 3.64% to $8.6 million in 2024, then plunged by 33.93% to $5.7 million in 2025, then slumped by 30.93% to $3.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $3.9 million, $5.1 million, and $5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.